NRx Pharmaceuticals Defends Arbitration Stance Against Kadima in Strategic Shift
Event summary
- NRx Pharmaceuticals issued a statement on June 25, 2026, responding to Kadima's public claims regarding the non-acquisition of Kadima by HOPE Therapeutics.
- The company is in arbitration with Kadima over failure to meet closing conditions, including clear title to assets and material adverse changes.
- NRx shifted its scientific direction towards neuronavigated TMS and neuroplastic drugs, partnering with Zeta Surgical for robotic TMS systems.
- FDA cleared the IND application for the SPARC-TMS trial combining NRX-101 with robotic neuronavigated TMS, set to start in fall 2026.
The big picture
NRx Pharmaceuticals is pivoting its scientific direction towards advanced, personalized medicine technologies, distancing itself from Kadima's approach. The shift aligns with broader industry trends towards precision medicine and robotic-assisted treatments. The outcome of the arbitration and the success of the SPARC-TMS trial will be critical in determining NRx's strategic trajectory.
What we're watching
- Arbitration Outcome
- Whether the San Diego courts will direct Dr. Feifel and Kadima back to arbitration, resolving the dispute equitably.
- Technological Integration
- The pace at which NRx can integrate robotic neuronavigated TMS systems into its treatment protocols.
- Regulatory Approvals
- How the FDA clearance of the SPARC-TMS trial will impact the development and commercialization of NRX-101.